Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Zhu, Zhengfei ^a,c   Yu, Weiwei ^b   Fu, Xiaolong ^a,c   Sun, Menghong ^a,c   Wei, Qiao ^a,c   Li, Dali ^a,c   Chen, Haiquan ^a,c   Xiang, Jiaqing ^a,c   Li, Hecheng ^a,c   Zhang, Yawei ^a,c   Zhao, Weixin ^a,c   Zhao, Kuaile ^a,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Esophageal carcinoma; Esophageal squamous cell carcinoma; Immunohistochemistry; p AKT1; Prognosis; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATED AKT1 PROTEIN; PROTEIN KINASE B; PROTEIN KINASE B BETA; STAT3 PROTEIN; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CORRELATION COEFFICIENT; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENDER; GENE ACTIVATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; ENZYMOLOGY; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PROGNOSIS; PROTEIN PROCESSING; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; BIOMARKERS, TUMOR; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, SQUAMOUS CELL; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84940782102     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0212-z     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Nakajima M, Kato H. Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2013;14:1345-54.
4. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15-31.
5. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21-6.
6. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007;109:658-67.
7. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004;8:448-53.
8. Hoshino M, Fukui H, Ono Y, Sekikawa A, Ichikawa K, Tomita S, et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology. 2007;74:15-21.
9. Gotoh M, Takiuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S, et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2007;37:652-7.
10. Kii T, Takiuchi H, Kawabe S, et al. Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens. Jpn J Clin Oncol. 2007;37:583-9.
11. Zhu Z, Yu W, Li H, Zhao K, Zhao W, Zhang Y, et al. Nodal skip metastasis is not a predictor of survival in thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2013;20:3052-8.
12. Zhu Z, Chen H, Yu W, Fu X, Xiang J, Li H, et al. Number of negative lymph nodes is associated with survival in thoracic esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Surg Oncol. 2014;21:2857-63.
13. Xiao X, Wang L, Wei P, Chi Y, Li D, Wang Q, et al. Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer. J Transl Med. 2013;11:151.
14. Skliris GP, Hube F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, et al. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology. 2008;52:355-69.
15. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer. 2008;112:1114-21.
16. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118:1173-80.
17. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Barón AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:111-9.
18. Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, et al. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Oncol Rep. 2005;28:49-54.
19. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107-15.
20. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007;31:493-9.
21. Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol. 2012;19:757-65.
22. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497-510.
23. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448:439-44.
24. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, et al. AKT1(E17K) in human solid tumours. Oncogene. 2008;27:5648-50.
25. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle. 2008;7:665-9.
26. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008;99:1265-8.
27. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261-74.
28. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455-64.
29. Veeriah S. Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition? J Chem Biol. 2012;5:115-7.
30. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 2009;69:5057-64.
31. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004;64:5232-6.
32. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003;89:2110-5.
33. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005;23:1473-82.
34. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:2930-6.
35. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011;117:1399-408.
36. Javle MM, Yu J, Khoury T, Chadha KS, Iyer RV, Foster J, et al. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 2006;21:1744-51.
37. Yoshioka A, Miyata H, Doki Y, Yasuda T, Yamasaki M, Motoori M, et al. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol Rep. 2008;19:1099-107.
38. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-83.